Fund Manager Summary on Bioxyne Ltd (ASX:BXN)
In February 2026, Cyan Investment Management commented that Bioxyne Ltd (ASX:BXN) saw H1 revenue more than double to $31.3m, prompting an upgrade to FY26 adjusted EBITDA guidance of $16.5–$19.0m and leaving material price upside against a market cap of $120m. Overall, fund managers increasingly view Bioxyne as a manufacturing-led play in medical cannabis and emerging psychedelics with strong operational momentum: earlier commentary highlighted FY25 revenue of $29.3m, positive cashflow and cash on hand, large manufacturing capacity (up to 6,000 kg monthly), TGA/GMP licensing via subsidiary Breathe Life Sciences, and a string of supply agreements in Australia and Europe (including referenced $7m and $5.6m deals and additional smaller contracts), underpinning an expanding international footprint in Germany and the UK; consensus sees durable structural tailwinds from regulatory liberalisation and growing market demand but flags execution and regulatory risk, sector volatility and the need to convert contracts into repeat, margin-accretive revenue as key near-term challenges. Actionable considerations emphasised by managers include prioritising disciplined capacity expansion and contract wins in Europe, protecting regulatory and quality credentials, careful cash and capital management given current market cap and planned growth, monitoring margin and cashflow conversion as guidance is realised, and treating M&A as a measured tool to consolidate position rather than a lever for rapid, dilutive expansion.
Commentary From The Managers
There are 5 insights from 3 fund managers regarding their investment in Bioxyne Ltd (ASX:BXN) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Cyan Investment Management
28 Feb 2026
$0.06
Summary
- Cyan Investment Management believes Bioxyne presents significant upside and continues to hold because H1 revenue more than doubled to $31.3m, FY26 adjusted EBITDA guidance was upgraded to $16.5–$19.0m and the current market cap of $120m leaves material price upside.
- Cyan Investment Management notes BXN was the Fund’s biggest winner, rising +54% over the period.
- Cyan Investment Management highlights Bioxyne is a Brisbane‑based manufacturer of medical cannabis and consumer health products, giving it end‑to‑end production capability.
- Cyan Investment Management observes H1 revenue reached $31.3m driven by increased demand across European and domestic markets.
- Cyan Investment Management emphasises the upgraded FY26 adjusted EBITDA guidance of $16.5–$19.0m as evidence of improving profitability and operating leverage.
- Cyan Investment Management believes the combination of strong near‑term earnings momentum and a $120m market cap implies meaningful upside potential from the current share price.
DMX Asset Management
28 Feb 2026
$0.06
Summary
- DMX Asset Management believes Bioxyne is a standout medicinal cannabis growth story and continues to hold, with a modest ~2% position sizing as confidence in the sustainability of its margins and growth builds.
- Bioxyne delivered what DMX considered the standout ASX micro-cap result this reporting season, reporting NPAT of $7.3m (up 121%) and upgrading FY26 EBITDA guidance by ~50% to $16.5–19m.
- At the midpoint of new guidance, Bioxyne is expected to generate ~$16m NPAT for FY26, implying a P/E of ~8x — a compelling valuation for a high-growth business.
- Bioxyne is Australia's leading GMP manufacturer of medicinal cannabis, now producing over 240,000 finished medicine products per month, and has constructed the world's largest GMP-certified cannabis pastilles manufacturing facility.
- The edibles/pastilles category is expected to grow from 1% to over 20% of Australian cannabis prescriptions by 2027, representing a significant market opportunity for Bioxyne's facilities.
- Bioxyne's entry into Germany — currently at 1% market share — is expected to be a major growth driver over the next 6–12 months, providing international diversification of its revenue base.
Tamim Funds Management
31 July 2025
$0.05
Summary
- Bioxyne Ltd. (ASX: BXN) is transforming from a dormant shell company into a sophisticated medical cannabis and psychedelics manufacturer.
- Founded through a reverse takeover in May 2023 by Sam Watson, the current CEO, who brings strategic vision and operational efficiency.
- Secured a comprehensive GMP manufacturing license in February 2024, allowing production of a wide range of products including flower, oils, gummies, MDMA, and psilocybin.
- Possesses fully automated production lines with capacity for 6,000 kilos of product monthly, providing scale and efficiency in manufacturing.
- Currently holds 10-15% market share in the Australian flower packing market, with revenues nearing $30 million annually in FY25.
- Operates as a contract manufacturer, generating consistent revenue while minimizing risks associated with brand development.
- Aims for international expansion, with agreements in Germany and the UK, targeting significant market opportunities.
- Financial projections include a current run rate of $45 million for FY26 and potential revenue of $100 million within two to three years.
- Maintains a lean operational cost structure of $500-600k monthly, indicating strong profitability prospects.
- Leadership under Sam Watson, who owns 29% of the company, is focused on strategic growth rather than rapid expansion.
- Positioning itself in the emerging psychedelics market with a contract for MDMA capsules for PTSD treatment.
- Emphasizes unique regulatory advantages and manufacturing expertise to differentiate from competitors.
- Bioxyne's business model focuses on manufacturing excellence, avoiding direct consumer sales for stability and profitability.
- Projected revenues and free cash flow generation indicate robust growth potential and market positioning.
- Overall, Bioxyne represents an intriguing opportunity for investors focused on the specialty pharmaceutical and medical cannabis sector.
Cyan Investment Management
31 July 2025
$0.05
Summary
- Bioxyne (BXN +17%) is focused on manufacturing medicinal cannabis and psilocybin products.
- The company reported a positive cash flow of $1.5m for the quarter and $6m for the year.
- Unaudited FY25 revenue of $29.3m exceeded guidance and is more than 200% above FY24.
- BXN, through its subsidiary Breathe Life Sciences, has expanded its manufacturing capacity in Brisbane.
- The company secured a new manufacturing and supply agreement for the German market.
- BXN is well-funded for further expansion, ending the quarter with $7.6m in cash on hand.
Cyan Investment Management
31 Mar 2025
$0.03
Summary
- Investment in Bioxyne Ltd (BXN), an Australian life sciences company.
- Focus on consumer health products in the expanding medical cannabis sector.
- Cyan Investment Management acknowledged strong financial results from BXN that have been overlooked by local investors.
- Belief that the market has underestimated the value generated by Bioxyne.
- Highlighting the significance of Breath Life Sciences, their subsidiary, as the first TGA-licensed manufacturer of CBD and THC products in Australia.
- Recent $7m manufacturing and supply agreement with NectarTek for consumer products supports the investment thesis.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Bioxyne Ltd (ASX:BXN)?
Fund managers including Cyan Investment Management, Tamim Funds Management and DMX Asset Management have invested in Bioxyne Ltd (ASX:BXN).
Why do fund managers invest in Bioxyne Ltd?
Fund managers invest in Bioxyne Ltd due to its strong financial performance and growth potential in the medical cannabis sector. The company has reported impressive revenue growth, exceeding guidance with FY25 sales of $29.3 million. Key factors include its comprehensive regulatory compliance, significant manufacturing capabilities, and strategic partnerships for international expansion. Bioxyne's lean operational costs and projected positive cash flow enhance its risk/reward profile. Analysts see potential for substantial revenue increases, further supported by its entrance into the psychedelic market.
What happened to Bioxyne Ltd (ASX:BXN)?
There have been no recent updates from fund managers regarding Bioxyne Ltd although fund managers including Cyan Investment Management and Tamim Funds Management have previously commented.
What is the short interest in Bioxyne Ltd (ASX:BXN)?
According to ASIC filings, there is negligible or no short interest in Bioxyne Ltd (ASX:BXN).
What does Bioxyne Ltd (ASX:BXN) do?
Bioxyne Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.